- Approval Id
- f5dd5a14f548a37c
- Drug Approval Emc Name
- DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder
- Drug Name
- DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder
- Company Address
- Field House, Station Approach, Harlow, Essex, CM20 2FB
- Company Website
- http://www.tevauk.com
- Company Telephone
- +44(0) 207 540 7000
- Company Medical Info Direct Line
- +44(0) 207 540 7117
- Company Medical Info Email
- medinfo@tevauk.com
- Company Medical Info Fax
- +44 (0) 207 000 1216
- Company Stock Availability
- 0800 590 502
- Atc Code
- R03AK07
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Teva UK Limited,
Ridings Point,
Whistler Drive,
Castleford, WF10 5HX,
United Kingdom
- Authorisation Number
- PLGB 00289/2438
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Teva UK Limited,
Ridings Point,
Whistler Drive,
Castleford, WF10 5HX,
United Kingdom
- Instruction Authorisation Number
- PLGB 00289/2438
- Instruction Authorisation Date
- 01/01/2021
- Instruction Composition
- Each delivered dose (the dose that leaves the mouthpiece) contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
This is equivalent to a metered dose of 200 micrograms budesonide and 6 micrograms of formoterol fumarate dihydrate.
Excipient(s) with known effect:
Each dose contains approximately 5 milligrams of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Inhalation powder.
White powder.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
\*\*Asthma\*\*
DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.
or
-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
DuoResp Spiromax is also indicated as reliever therapy for adults and adolescents (12 years and older) with mild asthma.
\*\*COPD\*\*
DuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) < 70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Asthma\*\*\*
The dosage of DuoResp Spiromax is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination medicinal products is initiated but also when the maintenance dose is adjusted. It is recommended that all patients with asthma are provided with a written personal asthma action plan. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of β2 adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of DuoResp Spiromax. Patients should be reassessed regularly by their prescriber/health care provider so that the dose of DuoResp Spiromax remains optimal. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required. When long-term control of symptoms is maintained with the lowest recommended dose, then the next step could include a test of inhaled corticosteroid alone.
For DuoResp Spiromax there are three treatment approaches:
\*\*A. DuoResp Spiromax maintenance therapy:\*\* DuoResp Spiromax is taken as regular maintenance treatment with a separate rapid-acting bronchodilator reliever inhaler.
\*\*B. DuoResp Spiromax maintenance and reliever therapy:\*\* DuoResp Spiromax is taken as regular maintenance treatment and as needed in response to symptoms.
\*\*C. DuoResp Spiromax reliever therapy:\*\* DuoResp Spiromax is taken as needed in response to symptoms.
\*\*\*\*A.\*\* \*\*DuoResp Spiromax maintenance therapy\*\*\*\*
Patients should be advised to have their separate rapid-acting bronchodilator reliever inhaler available for rescue use at all times.
\*Recommended doses:\*
Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.
Adolescents (12 years to 17 years): 1-2 inhalations twice daily.
In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include DuoResp Spiromax given once daily, when in the opinion of the prescriber, a long- acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.
Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy\*.\*
\*Children under 12 years:\* DuoResp Spiromax maintenance therapy is not recommended for children.
\*\*\*\*B.\*\* \*\*DuoResp Spiromax maintenance and reliever therapy\*\*\*\*
Patients take a daily maintenance dose of DuoResp Spiromax and in addition take DuoResp Spiromax as needed in response to symptoms. Patients should be advised to always have DuoResp Spiromax available for rescue use.
For patients taking DuoResp Spiromax as reliever, preventative use of DuoResp Spiromax for allergen- or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
DuoResp Spiromax maintenance and reliever therapy should especially be considered for patients with:
• inadequate asthma control and in frequent need of a reliever inhaler.
• asthma exacerbations in the past requiring medical intervention.
Close monitoring for dose-related adverse reactions is needed in patients who frequently take high numbers of DuoResp Spiromax as-needed inhalations.
\*Recommended doses:\*
Adults and adolescents (12 years and older): The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.
\*Children under 12 years:\* DuoResp Spiromax maintenance and reliever therapy is not recommended for children.
\*\*\*\*C.\*\* DuoResp Spiromax reliever therapy\*\*
Mild asthma patients take DuoResp Spiromax as needed in response to symptoms. This will provide relief by the rapid acting bronchodilation and also reduce inflammation.
Patients should be advised to always have DuoResp Spiromax available for rescue use.
For patients taking DuoResp Spiromax as reliever, preventative use of DuoResp Spiromax for allergen- or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
\*Recommended doses:\*
\*Adults and adolescents (12 years and older):\* Patients should take 1 inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
If a patient finds the treatment less effective or experiences progressive deterioration of symptoms despite taking DuoResp Spiromax as needed the patient should seek medical attention as soon as possible (see section 4.4).
A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be reassessed for alternative explanations of persisting symptoms. Patients should be assessed at regular intervals according to local practice to determine whether their as-needed treatment with DuoResp Spiromax remains optimal or whether regular scheduled treatment with inhaled corticosteroid-containing maintenance medication should be initiated.
\*Children under 12 years:\* DuoResp Spiromax reliever therapy is not recommended for children.
\*\*\*COPD\*\*\*
\*Recommended doses:\*
Adults (18 years and older): 2 inhalations twice daily
\*\*Special populations:\*\*
\*Elderly patients (\*≥\*65 years old)\*
There are no special dosing requirements for elderly patients.
\*Patients with renal or hepatic impairment\*
There are no data available for use of a fixed-dose combination of budesonide and formoterol fumarate dihydrate in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.
\*Paediatric population\*
The safety and efficacy of DuoResp Spiromax in paediatric patients below 12 years of age have not been established. No data are available.
This medicinal product is not recommended for use in children under the age of 12 years.
\*\*Method of administration\*\*
For inhalation use only.
Spiromax is a breath actuated, inspiratory flow-driven inhaler, which means that the active substances are delivered into the airways when the patient inhales through the mouthpiece. Moderate and severe asthmatic patients were shown to be able to generate sufficient inspiratory flow rate for Spiromax to deliver the therapeutic dose (see section 5.1).
DuoResp Spiromax should be used correctly in order to achieve effective treatment. As such, the patients should be advised to read the patient information leaflet carefully and follow the instructions for use as detailed in the leaflet.
The use of DuoResp Spiromax follows three steps: open, breathe and close which are outlined below.
\*\*Open:\*\* Hold the Spiromax with the mouthpiece cover at the bottom and open the mouthpiece cover by folding it down until it is fully opened when one click is heard.
\*\*Breathe:\*\* Place the mouthpiece between the teeth with the lips closed around the mouthpiece, do not bite the mouthpiece of the inhaler. Breathe in forcefully and deeply through the mouthpiece. Remove the Spiromax from mouth and hold the breath for 10 seconds or as long as comfortable for the patients.
\*\*Close:\*\* Breathe out gently and close the mouthpiece cover.
It is also important to advise patients not to shake the inhaler before use and not to breathe out through the Spiromax and not to block the air vents when they are preparing the “Breathe” step.
Patients should also be advised to rinse their mouth with water after inhaling (see section 4.4). The patient may notice a taste when using DuoResp Spiromax due to the lactose excipient.4.3 Contraindications
Hypersensitivity to the active substances or the excipient listed in section 6.1.4.4 Special warnings and precautions for use
Dosing advice
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of DuoResp Spiromax remains optimal. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of DuoResp Spiromax. When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Regular review of patients as treatment is stepped down is important..
Patients should be advised to have their rescue inhaler available at all times, either DuoResp Spiromax (for asthma patients using DuoResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using DuoResp Spiromax as maintenance therapy only).
It is recommended that the dose is tapered when the treatment is discontinued and should not be stopped abruptly. Complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm diagnosis of asthma.
Patients should be reminded to take their DuoResp Spiromax maintenance dose as prescribed, even when asymptomatic. The prophylactic use of DuoResp Spiromax, e.g. before exercise, has not been studied. The reliever inhalations of DuoResp Spiromax should be taken in response to symptoms but are not intended for regular prophylactic use, e.g. before exercise. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
Deterioration of disease
Serious asthma-related adverse reactions and exacerbations may occur during treatment with DuoResp Spiromax. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with DuoResp Spiromax.
If patients find the treatment ineffective, or exceed the highest recommended dose of DuoResp Spiromax, medical attention must be sought (see section 4.2). Sudden and progressive deterioration in control of asthma or COPD is potentially life-threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.
Patients should not be initiated on DuoResp Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
\*\*Systemic effects\*\*
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids.
Possible systemic effects include Cushing´s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see section 4.8).
\*Visual disturbance\*
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
\*\*Effects on bone density\*\*
Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have co-existing risk factors for osteoporosis.
Long-term studies with inhaled budesonide in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect of a budesonide/formoterol fumarate dihydrate fixed-dose combination at higher doses is available.
\*\*Adrenal function\*\*
Treatment with supplementary systematic steroids or inhaled budesonide should not be stopped abruptly.
The prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may also result in clinically significant adrenal suppression. Therefore additional systemic corticosteroid cover should be considered during periods of stress such as severe infections or elective surgery. Rapid reduction in the dose of steroids can induce acute adrenal crisis. Symptoms and signs which might be seen in acute adrenal crisis may be somewhat vague but may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycaemia.
Paradoxical bronchospasm
Paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath, after dosing. If the patient experiences paradoxical bronchospasm DuoResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway (see section 4.8).
\*\*Transfer from oral therapy\*\*
If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to a budesonide/formoterol fumarate fixed-dose combination therapy.
The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid-dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances hypothalamic pituitary adrenocortical (HPA) axis function should be monitored regularly.
During transfer from oral therapy to a budesonide/formoterol fumarate fixed-dose combination therapy, a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.
\*\*Oral infections\*\*
To minimise the risk of oropharyngeal candida infection, the patient should be instructed to rinse their mouth out with water after inhaling the dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations (see section 4.2).
Paediatric population
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible. The benefits of the corticosteroid therapy and the possible risks of growth suppression must be carefully weighed. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Limited data from long-term studies suggest that most children and adolescents treated with inhaled budesonide will ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment.
\*\*COPD population\*\*
There are no clinical study data on DuoResp Spiromax available in COPD patients with a pre-bronchodilator FEV1 >50% predicted normal and with a post-bronchodilator FEV1 <70% predicted normal (see section 5.1).
\*Pneumonia\*
An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
\*\*Interaction with other medicinal products\*\*
Concomitant treatment with itraconazole, ritonavir or other potent CYP3A4 inhibitors should be avoided (see section 4.5). If this is not possible the time interval between administrations of the interacting medicinal products should be as long as possible. In patients using potent CYP3A4 inhibitors, a budesonide/formoterol fumarate fixed-dose combination is not recommended.
\*\*Caution with special diseases\*\*
A fixed-dose combination of budesonide and formoterol fumarate dihydrate should be administered with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
Caution should be observed when treating patients with prolongation of the QTc-interval. Formoterol itself may induce prolongation of the QTc-interval.
The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Additional blood glucose controls should be considered in diabetic patients.
\*\*β2 adrenoceptor agonists\*\*
Potentially serious hypokalaemia may result from high doses of β2 adrenoceptor agonists. Concomitant treatment of β2 adrenoceptor agonists with medicinal products which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the β2 adrenoceptor agonist.
Treatment with β2 adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased. It is recommended that serum potassium levels are monitored during these circumstances.
\*\*Excipients\*\*
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interactions\*\*
Potent inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors) are likely to markedly increase plasma levels of budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and budesonide should be as long as possible (see section 4.4). In patients using potent CYP3A4 inhibitors, a fixed-dose combination of budesonide and formoterol fumarate dihydrate maintenance and reliever therapy is not recommended.
The potent CYP3A4 inhibitor ketoconazole, 200 mg once daily, increased plasma levels of concomitantly orally administered budesonide (single dose 3 mg) on average six-fold. When ketoconazole was administered 12 hours after budesonide the concentration was on average increased only three-fold showing that separation of the administration times can reduce the increase in plasma levels. Limited data about this interaction for high-dose inhaled budesonide indicates that marked increases in plasma levels (on average four fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000 micrograms).
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side- effects.
\*\*Pharmacodynamic interactions\*\*
β adrenergic blockers can weaken or inhibit the effect of formoterol. A fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate should therefore not be given together with \*\*β\*\* adrenergic blockers (including eye drops) unless there are compelling reasons.
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.
In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2 sympathomimetics.
Concomitant treatment with monoamine oxidase inhibitors including medicinal products with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions.
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Concomitant use of other \*\*β\*\* adrenergic medicinal products and anticholinergic medicinal products can have a potentially additive bronchodilating effect.
Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.
Budesonide and formoterol have not been observed to interact with any other medicinal products used in the treatment of asthma.
\*\*Paediatric population\*\*
Interaction studies have only been performed in adults.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
For a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate or the concomitant treatment with formoterol and budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-fetal development study in the rat, showed no evidence of any additional effect from the combination.
There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse reactions in reproduction studies at very high systemic exposure levels (see section 5.3).
Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses.
Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.
During pregnancy, a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
\*\*Breast-feeding\*\*
Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
\*\*Fertility\*\*
There is no data available on the potential effect of budesonide on fertility. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure (see section 5.3).4.7 Effects on ability to drive and use machines
DuoResp Spiromax has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
Since DuoResp Spiromax contains both budesonide and formoterol, the same pattern of adverse reactions as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment. In a 3-year clinical trial with budesonide in COPD, skin bruises and pneumonia occurred at a frequency of 10% and 6%, respectively, compared with 4% and 3% in the placebo group (p<0.001 and p<0.01, respectively).
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions, which have been associated with budesonide or formoterol, are given below and listed by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, < 1/100), rare (≥1/10,000, < 1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
\*\*Table 1\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reaction\*\* |
| Infections and infestations | Common | Candida infections in the oropharynx, pneumonia (in COPD patients) |
| Immune system disorders | Rare | Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction |
| Endocrine disorders | Very rare | Cushing´s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density |
| Metabolism and nutrition disorders | Rare | Hypokalaemia |
| Very rare | Hyperglycaemia |
| Psychiatric disorders | Uncommon | Aggression, psychomotor hyperactivity, anxiety, sleep disorders |
| Very rare | Depression, behavioural changes (predominantly in children) |
| Nervous system disorders | Common | Headache, tremor |
| Uncommon | Dizziness |
| Very rare | Taste disturbances |
| Eye disorders | Very rare | Cataract and glaucoma |
| Uncommon | Vision, blurred (see also section 4.4) |
| Cardiac disorders | Common | Palpitations |
| Uncommon | Tachycardia |
| Rare | Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles |
| Very rare | Angina pectoris. Prolongation of QTc-interval |
| Vascular disorders | Very rare | Variations in blood pressure |
| Respiratory, thoracic and mediastinal disorders | Common | Mild irritation in the throat, coughing, Dysphonia including hoarseness |
| Rare | Bronchospasm |
| Very rare | Paradoxical bronchospasm |
| Gastrointestinal disorders | Uncommon | Nausea |
| Skin and subcutaneous tissue disorders | Uncommon | Bruises |
| Musculoskeletal and connective tissue disorders | Uncommon | Muscle cramps |
\*\*Description of selected adverse reactions\*\*
Candida infection in the oropharynx is due to active substance deposition. Advising the patient to rinse the mouth out with water after each dose will minimise the risk. Oropharyngeal Candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroid. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.
Paradoxical bronchospasm may occur very rarely, affecting less than 1 in 10,000 people, with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. DuoResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing´s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.
Treatment with β2 adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
An overdose of formoterol would likely lead to effects that are typical for β2 adrenoceptor agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction raised no safety concerns.
Acute overdose with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects, such as hypercorticism and adrenal suppression, may appear.
If DuoResp Spiromax therapy has to be withdrawn due to overdose of the formoterol component of the medicinal product, provision of appropriate inhaled corticosteroid therapy must be considered.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics and other drugs for obstructive airway diseases.
ATC code: R03AK07
\*\*Mechanism of action and pharmacodynamic effects\*\*
DuoResp Spiromax contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used either as maintenance and reliever therapy, or as maintenance treatment of asthma.
\*Budesonide\*
Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse reactions than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.
\*Formoterol\*
Formoterol is a selective β2 adrenoceptor agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose- dependent, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose.
\*\*Clinical efficacy and safety\*\*
\*\*\*Asthma\*\*\*
\*Budesonide/formoterol maintenance therapy\*
Clinical studies in adults have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations.
In two 12-week studies the effect on lung function of budesonide/formoterol was equal to that of the free combination of budesonide and formoterol, and exceeded that of budesonide alone. All treatment arms used a short-acting β2 adrenoceptor agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.
\*Budesonide/formoterol maintenance and reliever therapy\*
A total of 12076 asthma patients were included in 5 double-blind clinical studies (4447 were randomised to budesonide/formoterol maintenance and reliever therapy) for 6 or 12 months. Patients were required to be symptomatic despite use of inhaled glucocorticosteroids.
Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5 studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study 735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study 734) (see table 2). In Study 735, lung function, symptom control, and reliever use were similar in all treatment groups. In Study 734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5 studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.
\*\*Table 2 Overview of severe exacerbations in clinical studies (budesonide / formoterol maintenance and reliever therapy)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Study No. Duration\*\* | \*\*Treatment groups\*\* | \*\*N\*\* | \*\*Severe exacerbations\*\*a | |
| \*\*Events\*\* | \*\*Events/ patient-year\*\* |
| \*\*Study 735\*\* \*\*6 months\*\* | \*\*Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + as needed\*\* | \*\*1103\*\* | \*\*125\*\* | \*\*0.23\*\*b |
| Budesonide/Formoterol Fumarate Dihydrate 320/9 µg bd + terbutaline 0.4 mg as needed | 1099 | 173 | 0.32 |
| Salmeterol/fluticasone 2 x 25/125 µg bd + terbutaline 0.4 mg as needed | 1119 | 208 | 0.38 |
| \*\*Study 734\*\* \*\*12 months\*\* | \*\*Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + as needed\*\* | \*\*1107\*\* | \*\*194\*\* | \*\*0.19\*\*b |
| Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + formoterol 4.5 µg as needed | 1137 | 296 | 0.29 |
| Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + terbutaline 0.4 mg as needed | 1138 | 377 | 0.37 |
aHospitalisation/emergency room treatment or treatment with oral steroids
bReduction in exacerbation rate is statistically significant (P value <0.01) for both comparisons
Comparable efficacy and safety in adolescents and adults was demonstrated in 6 double-blind studies, comprising the 5 studies mentioned above and an additional study using a higher maintenance dose of 160/4.5 micrograms, two inhalations twice daily. These assessments were based on a total of 14385 asthma patients of whom 1847 were adolescents. The number of adolescent patients taking more than 8 inhalations on at least one day as part of budesonide/formoterol maintenance and reliever therapy was limited and such use was infrequent.
In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.
\*\*\*Budesonide/formoterol reliever therapy (Therapy C in Section 4.2)\*\*\*
A total of 8064 adult and adolescent asthma patients with mild asthma were included in 2 randomised, double-blind, double-dummy, placebo-controlled, 52-week efficacy and safety studies (SYGMA 1 and SYGMA 2). Across both studies, 889 patients were adolescents. At study entry, patients were required to be uncontrolled on only short-acting inhaled bronchodilator as needed or controlled on a low dose of inhaled corticosteroids or a leukotriene receptor agonist plus a short- acting inhaled bronchodilator as needed.
A further 1565 adult asthma patients were included in 2 randomised, open-label, 52-week investigator-sponsored efficacy and safety studies (Novel START and PRACTICAL). In Novel START, patients had used as-needed short-acting inhaled bronchodilator (without any other asthma medication) in the 3 months before study entry, while in PRACTICAL, patients had used as-needed short-acting inhaled bronchodilator alone or a low to medium dose of inhaled corticosteroids plus short- acting inhaled bronchodilator as needed at study entry.
\*Exacerbation rate\*
The primary endpoint in SYGMA 2 and PRACTICAL was the annual severe exacerbation rate, while the rate of all exacerbations was the primary endpoint in Novel START. The primary endpoint in SYGMA 1 was 'well-controlled asthma weeks' (WCAW), a composite measure of asthma control.
Table 3 summarises the rate of exacerbations by treatment group in the 4 studies. SYGMA 2 showed that the severe exacerbation rate with budesonide/formoterol reliever therapy was comparable to budesonide maintenance treatment plus a short- acting β2 agonist (SABA) reliever and that this protection against severe exacerbations was achieved with a 75% reduction in median inhaled steroid load. In PRACTICAL, a statistically significant reduction in the severe exacerbation rate was observed with budesonide/formoterol reliever therapy compared with budesonide maintenance treatment plus a SABA reliever. In Novel START, budesonide/formoterol reliever therapy provided a statistically significant reduction in the exacerbation rate compared with a SABA reliever.
\*\*Table 3 Overview of asthma exacerbations in clinical studies (budesonide/formoterol reliever therapy)\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Study No. Duration Blinding\*\* | \*\*Treatment groupsa\*\* | \*\*n\*\* | \*\*Exacerbations\*\*b | | \*\*Rate ratio\*\* \*\*(2-sided 95% CI) versus budesonide/ formoterol\*\* |
| \*\*Events\*\* | \*\*Events/ patient-year\*\* |
| \*\*Severe exacerbations (primary endpoint in SYGMA 2 and PRACTICAL, secondary endpoint in SYGMA 1)\*\* | | | | | |
| \*\*SYGMA 2\*\* \*\*12 months\*\* \*\*Double blind\*\* | \*\*Placebo bd + budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*2084\*\* | \*\*217\*\* | \*\*0.11\*\* | \*\*NA\*\* |
| Budesonide/formoterol 160 µg bd + terbutaline 0.4 mg as needed | 2083 | 221 | 0.12 | 0.97 (0.78, 1.20) p = 0.754c |
| \*\*PRACTICAL\*\* \*\*12 months\*\* \*\*Open label\*\* | \*\*Budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*437\*\* | \*\*48\*\* | \*\*0.119\*\* | NA |
| Budesonide/formoterol 160/4.5 µg bd + terbutaline 0.4 mg as needed | 448 | 68 | 0.172 | 0.69 (0.48, 1.00) p = 0.049 |
| \*\*SYGMA 1\*\* \*\*12 months\*\* \*\*Double blind\*\* | \*\*Placebo bd + budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*1277\*\* | \*\*77\*\* | \*\*0.07\*\* | NA |
| Placebo bd + terbutaline 0.4 mg as needed | 1277 | 188 | 0.20 | 0.36 (0.27, 0.49) p <0.001 |
| Budesonide 160 µg bd + terbutaline 0.4 mg as needed | 1282 | 89 | 0.09 | 0.83 (0.59, 1.16) p = 0.279 |
| \*\*All exacerbations (primary endpoint in Novel START)\*\* | | | | | |
| \*\*Novel START\*\* \*\*12 months\*\* \*\*Open label\*\* | \*\*Budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*220\*\* | \*\*37\*\* | \*\*0.195\*\* | NA |
| Budesonide 160 µg bd + salbutamol 200 µg as needed | 225 | 32 | 0.175 | 1.12 (0.70, 1.79) p = 0.65 |
| Salbutamol 200 µg as needed | 223 | 74 | 0.400 | 0.49 (0.33, 0.72) p < 0.001 |
a Budesonide 160 µg (delivered dose) corresponds to budesonide 200 µg (metered dose).
b Severe exacerbations were defined as deteriorating asthma requiring treatment with systemic steroids for at least 3 days, or hospital admission or emergency room visit due to asthma requiring systemic steroids. All exacerbations in Novel START were defined as worsening of asthma resulting in an urgent medical review or a prescription of systemic steroids for any duration or high β2 agonist use.
c The upper limit (1.16) of the 1-sided 95% CI for the rate ratio was below the pre- specified non-inferiority limit (1.20).
\*Asthma control\*
In SYGMA 1, in terms of the WCAW, budesonide/formoterol reliever therapy was superior to a SABA reliever (mean percentage well controlled asthma weeks: 34.4% versus 31.1%, respectively; odds ratio 1.14 [95% CI 1.00 to 1.30], p-value = 0.046) and was inferior to budesonide maintenance treatment plus a SABA reliever (34.4% versus 44.4% weeks, respectively; odds ratio 0.64 [95% CI 0.57 to 0.73], lower limit of the CI ≥ 0.8 for non-inferiority).
Improvements in asthma control (as defined by ACQ5) in patients using budesonide/formoterol reliever therapy were superior to improvements in patients using a SABA as needed (SYGMA 1: mean difference −0.15, 95% CI −0.20 to −0.11, p-value < 0.001; Novel START: −0.15; 95% CI, −0.24 to −0.06). In the SYGMA studies and Novel START, improvements in asthma control were lower for budesonide/formoterol reliever therapy compared to budesonide maintenance treatment plus a SABA reliever (SYGMA 1: 0.15, 95% CI 0.10 to 0.20; SYGMA 2: 0.11, 95% CI 0.07 to 0.15, both p-values < 0.001; Novel START: 0.14; 95% CI, 0.05 to 0.23) but there was no difference between the groups in PRACTICAL (0.06, 95% CI, −0.005 to 0.12, p =0.07). For all comparisons, the mean difference in treatment effect upon ACQ5 were not clinically meaningful (as assessed by a difference of greater than or equal to 0.5). These results were observed in a clinical study setting with considerably higher adherence to budesonide maintenance dosing than expected in real life.
\*Lung function\*
In SYGMA 1, improvements in mean pre-bronchodilator FEV1 compared to baseline were statistically significantly larger for patients on budesonide/formoterol reliever therapy compared to patients using a SABA reliever (53.8 mL; 95% CI 29.1 to 78.5; p <0.001).
In both SYGMA studies, statistically significantly smaller improvements in FEV1 were observed for budesonide/formoterol reliever therapy compared to budesonide maintenance treatment plus a SABA reliever (SYGMA 1: −54.3 mL; 95% CI −78.8 to −29.8; p <0.001; SYGMA 2: −32.6 mL; 95% CI −53.7 to −11.4; p = 0.003); For both comparisons, the mean differences in treatment effect were small (approximately 30 to 55 mL, equating to approximately 2% of the baseline mean). In Novel START and PRACTICAL, there were no significant differences in FEV1 versus SABA (Novel START: 0.03 L; 95% CI, −0.006 to 0.07) or versus budesonide maintenance treatment plus a SABA reliever (Novel START: 0.004 L; 95% CI, −0.03 to 0.04; PRACTICAL: 0.006 L; 95% CI −0.026 to 0.04; p = 0·69).
\*COPD\*
In two 12-month studies, the effect on lung function and the rate of exacerbation (defined as courses of oral steroids and/or course of antibiotics and/or hospitalisations) in patients with moderate to severe COPD was evaluated. The inclusion criteria for both studies was pre-bronchodilator FEV1 <50% predicted normal. Median post-bronchodilator FEV1 at inclusion in the trials was 42% predicted normal.. The mean number of exacerbations per year (as defined above) was significantly reduced with budesonide/formoterol as compared with treatment with formoterol alone or placebo (mean rate 1.4 compared with 1.8-1.9 in the placebo/formoterol group). The mean number of days on oral corticosteroids/patient during the 12 months was slightly reduced in the budesonide/formoterol group (7-8 days/patient/year compared with 11-12 and 9-12 days in the placebo and formoterol groups, respectively). For changes in lung-function parameters, such as FEV1, budesonide/formoterol was not superior to treatment with formoterol alone.
\*\*Peak Inspiratory Flow Rate through the Spiromax Device\*\*
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device(containing placebo). The impact of enhanced training in dry powder inhaler inhalation technique on inhalation speed and volume was also assessed in these subject groups. The data from the study indicated that regardless of age and underlying disease severity, children, adolescents and adults with asthma as well as patients with COPD were able to able to achieve inspiratory flow rates through the Spiromax device that were similar to those generated through the marketed multi-dose dry powder inhaler device. The mean PIFR achieved by patients with asthma or COPD was over 60L/min, a flow rate at which both devices studied are known to deliver comparable amounts of drug to the lungs. Very few patients had PIFRs below 40L/min; when PIFRs were less than 40L/min there appeared to be no clustering by age or disease severity.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
The fixed-dose combination of budesonide and formoterol, and the corresponding monoproducts have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively. In spite of this, a small increase in cortisol suppression was seen after administration of fixed-dose combination compared to the monoproducts. The difference is considered not to have an impact on clinical safety.
There was no evidence of pharmacokinetic interactions between budesonide and formoterol.
Pharmacokinetic parameters for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as the fixed-dose combination. For budesonide, AUC was slightly higher, rate of absorption more rapid and maximal plasma concentration higher after administration of the fixed combination. For formoterol, maximal plasma concentration was similar after administration of the fixed combination. Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is reached within 30 minutes after inhalation. In studies, mean lung deposition of budesonide after inhalation via the powder inhaler ranged from 32% to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose. In children 6-16 years of age the lung deposition falls in the same range as in adults for the same given dose. The resulting plasma concentrations were not determined.
Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation. In studies the mean lung deposition of formoterol after inhalation via the powder inhaler ranged from 28% to 49% of the delivered dose. The systemic bioavailability is about 61% of the delivered dose.
\*\*Distribution\*\*
Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6-beta-hydroxy-budesonide and 16-alfa-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.
\*\*Elimination\*\*
The major part of a dose of formoterol is transformed by liver metabolism followed by renal elimination. After inhalation, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.
Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are eliminated in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
\*\*Pharmacokinetic/pharmacodynamic relationship(s)\*\*
The pharmacokinetics of budesonide or formoterol in children and patients with renal failure are unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.
\*\*DuoResp Spiromax pharmacokinetic profile\*\*
In pharmacokinetic studies with and without a charcoal blockage, DuoResp Spiromax was evaluated by comparing it with an alternative authorised fixed-dose combination inhaled product containing the same active substances, budesonide and formoterol and has been shown to be equivalent in both systemic exposure (safety) and pulmonary deposition (efficacy).
\*\*Linearity/non-linearity\*\*
Systemic exposure for both budesonide and formoterol correlates in a linear fashion to administered dose.5.3 Preclinical safety data
The toxicity observed in animal studies with budesonide and formoterol, given in combination or separately, were effects associated with exaggerated pharmacological activity.
In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant in humans.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Lactose monohydrate (which contains milk proteins).6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years.
After opening the foil wrap: 12 months.6.4 Special precautions for storage
Do not store above 25°C.
Keep the mouthpiece cover closed after removal of the foil wrap.6.5 Nature and contents of container
The inhaler is white with a semi-transparent wine red mouthpiece cover. The drug/mucosal contact parts of the inhaler are made of acrylonitrile butadiene styrene (ABS), polyethylene (PE), and polypropylene (PP). Each inhaler contains 120 doses and is foil-wrapped.
Pack sizes of 1, 2 or 3 inhalers.
Not all pack-sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each delivered dose (the dose that leaves the mouthpiece) contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
This is equivalent to a metered dose of 200 micrograms budesonide and 6 micrograms of formoterol fumarate dihydrate.
Excipient(s) with known effect:
Each dose contains approximately 5 milligrams of lactose (as monohydrate).
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Inhalation powder.
White powder.
## Clinical Particulars
4.1 Therapeutic indications
\*\*Asthma\*\*
DuoResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:
-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.
or
-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
DuoResp Spiromax is also indicated as reliever therapy for adults and adolescents (12 years and older) with mild asthma.
\*\*COPD\*\*
DuoResp Spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) < 70% predicted normal (post bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.4.2 Posology and method of administration
\*\*Posology\*\*
\*\*\*Asthma\*\*\*
The dosage of DuoResp Spiromax is individual and should be adjusted to the severity of the disease. This should be considered not only when treatment with combination medicinal products is initiated but also when the maintenance dose is adjusted. It is recommended that all patients with asthma are provided with a written personal asthma action plan. If an individual patient should require a combination of doses other than those available in the combination inhaler, appropriate doses of β2 adrenoceptor agonists and/or corticosteroids by individual inhalers should be prescribed.
Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of DuoResp Spiromax. Patients should be reassessed regularly by their prescriber/health care provider so that the dose of DuoResp Spiromax remains optimal. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained.When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required. When long-term control of symptoms is maintained with the lowest recommended dose, then the next step could include a test of inhaled corticosteroid alone.
For DuoResp Spiromax there are three treatment approaches:
\*\*A. DuoResp Spiromax maintenance therapy:\*\* DuoResp Spiromax is taken as regular maintenance treatment with a separate rapid-acting bronchodilator reliever inhaler.
\*\*B. DuoResp Spiromax maintenance and reliever therapy:\*\* DuoResp Spiromax is taken as regular maintenance treatment and as needed in response to symptoms.
\*\*C. DuoResp Spiromax reliever therapy:\*\* DuoResp Spiromax is taken as needed in response to symptoms.
\*\*\*\*A.\*\* \*\*DuoResp Spiromax maintenance therapy\*\*\*\*
Patients should be advised to have their separate rapid-acting bronchodilator reliever inhaler available for rescue use at all times.
\*Recommended doses:\*
Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.
Adolescents (12 years to 17 years): 1-2 inhalations twice daily.
In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include DuoResp Spiromax given once daily, when in the opinion of the prescriber, a long- acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.
Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy\*.\*
\*Children under 12 years:\* DuoResp Spiromax maintenance therapy is not recommended for children.
\*\*\*\*B.\*\* \*\*DuoResp Spiromax maintenance and reliever therapy\*\*\*\*
Patients take a daily maintenance dose of DuoResp Spiromax and in addition take DuoResp Spiromax as needed in response to symptoms. Patients should be advised to always have DuoResp Spiromax available for rescue use.
For patients taking DuoResp Spiromax as reliever, preventative use of DuoResp Spiromax for allergen- or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
DuoResp Spiromax maintenance and reliever therapy should especially be considered for patients with:
• inadequate asthma control and in frequent need of a reliever inhaler.
• asthma exacerbations in the past requiring medical intervention.
Close monitoring for dose-related adverse reactions is needed in patients who frequently take high numbers of DuoResp Spiromax as-needed inhalations.
\*Recommended doses:\*
Adults and adolescents (12 years and older): The recommended maintenance dose is 2 inhalations per day, given either as one inhalation in the morning and evening or as 2 inhalations in either the morning or evening. For some patients a maintenance dose of 2 inhalations twice daily may be appropriate. Patients should take 1 additional inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.
\*Children under 12 years:\* DuoResp Spiromax maintenance and reliever therapy is not recommended for children.
\*\*\*\*C.\*\* DuoResp Spiromax reliever therapy\*\*
Mild asthma patients take DuoResp Spiromax as needed in response to symptoms. This will provide relief by the rapid acting bronchodilation and also reduce inflammation.
Patients should be advised to always have DuoResp Spiromax available for rescue use.
For patients taking DuoResp Spiromax as reliever, preventative use of DuoResp Spiromax for allergen- or exercise-induced bronchoconstriction should be discussed between physician and patient; the recommended use should take into consideration the frequency of need. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
\*Recommended doses:\*
\*Adults and adolescents (12 years and older):\* Patients should take 1 inhalation as needed in response to symptoms. If symptoms persist after a few minutes, an additional inhalation should be taken. Not more than 6 inhalations should be taken on any single occasion.
If a patient finds the treatment less effective or experiences progressive deterioration of symptoms despite taking DuoResp Spiromax as needed the patient should seek medical attention as soon as possible (see section 4.4).
A total daily dose of more than 8 inhalations is not normally needed; however, a total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be reassessed for alternative explanations of persisting symptoms. Patients should be assessed at regular intervals according to local practice to determine whether their as-needed treatment with DuoResp Spiromax remains optimal or whether regular scheduled treatment with inhaled corticosteroid-containing maintenance medication should be initiated.
\*Children under 12 years:\* DuoResp Spiromax reliever therapy is not recommended for children.
\*\*\*COPD\*\*\*
\*Recommended doses:\*
Adults (18 years and older): 2 inhalations twice daily
\*\*Special populations:\*\*
\*Elderly patients (\*≥\*65 years old)\*
There are no special dosing requirements for elderly patients.
\*Patients with renal or hepatic impairment\*
There are no data available for use of a fixed-dose combination of budesonide and formoterol fumarate dihydrate in patients with hepatic or renal impairment. As budesonide and formoterol are primarily eliminated via hepatic metabolism, an increased exposure can be expected in patients with severe liver cirrhosis.
\*Paediatric population\*
The safety and efficacy of DuoResp Spiromax in paediatric patients below 12 years of age have not been established. No data are available.
This medicinal product is not recommended for use in children under the age of 12 years.
\*\*Method of administration\*\*
For inhalation use only.
Spiromax is a breath actuated, inspiratory flow-driven inhaler, which means that the active substances are delivered into the airways when the patient inhales through the mouthpiece. Moderate and severe asthmatic patients were shown to be able to generate sufficient inspiratory flow rate for Spiromax to deliver the therapeutic dose (see section 5.1).
DuoResp Spiromax should be used correctly in order to achieve effective treatment. As such, the patients should be advised to read the patient information leaflet carefully and follow the instructions for use as detailed in the leaflet.
The use of DuoResp Spiromax follows three steps: open, breathe and close which are outlined below.
\*\*Open:\*\* Hold the Spiromax with the mouthpiece cover at the bottom and open the mouthpiece cover by folding it down until it is fully opened when one click is heard.
\*\*Breathe:\*\* Place the mouthpiece between the teeth with the lips closed around the mouthpiece, do not bite the mouthpiece of the inhaler. Breathe in forcefully and deeply through the mouthpiece. Remove the Spiromax from mouth and hold the breath for 10 seconds or as long as comfortable for the patients.
\*\*Close:\*\* Breathe out gently and close the mouthpiece cover.
It is also important to advise patients not to shake the inhaler before use and not to breathe out through the Spiromax and not to block the air vents when they are preparing the “Breathe” step.
Patients should also be advised to rinse their mouth with water after inhaling (see section 4.4). The patient may notice a taste when using DuoResp Spiromax due to the lactose excipient.4.3 Contraindications
Hypersensitivity to the active substances or the excipient listed in section 6.1.4.4 Special warnings and precautions for use
Dosing advice
Patients should be reassessed regularly by their prescriber/healthcare provider so that the dose of DuoResp Spiromax remains optimal. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Once asthma symptoms are controlled, consideration may be given to gradually reducing the dose of DuoResp Spiromax. When it is appropriate to titrate down to a lower strength than is available for DuoResp Spiromax, a change to an alternative fixed-dose combination of budesonide and formoterol fumarate containing a lower dose of the inhaled corticosteroid is required.
Regular review of patients as treatment is stepped down is important..
Patients should be advised to have their rescue inhaler available at all times, either DuoResp Spiromax (for asthma patients using DuoResp Spiromax as maintenance and reliever therapy) or a separate rapid-acting bronchodilator (for asthma patients using DuoResp Spiromax as maintenance therapy only).
It is recommended that the dose is tapered when the treatment is discontinued and should not be stopped abruptly. Complete withdrawal of inhaled corticosteroids should not be considered unless it is temporarily required to confirm diagnosis of asthma.
Patients should be reminded to take their DuoResp Spiromax maintenance dose as prescribed, even when asymptomatic. The prophylactic use of DuoResp Spiromax, e.g. before exercise, has not been studied. The reliever inhalations of DuoResp Spiromax should be taken in response to symptoms but are not intended for regular prophylactic use, e.g. before exercise. In case of frequent need of bronchodilation without corresponding need for an increased dose of inhaled corticosteroids, an alternative reliever should be used.
Deterioration of disease
Serious asthma-related adverse reactions and exacerbations may occur during treatment with DuoResp Spiromax. Patients should be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation with DuoResp Spiromax.
If patients find the treatment ineffective, or exceed the highest recommended dose of DuoResp Spiromax, medical attention must be sought (see section 4.2). Sudden and progressive deterioration in control of asthma or COPD is potentially life-threatening and the patient should undergo urgent medical assessment. In this situation, consideration should be given to the need for increased therapy with corticosteroids, e.g. a course of oral corticosteroids, or antibiotic treatment if an infection is present.
Patients should not be initiated on DuoResp Spiromax during an exacerbation, or if they have significantly worsening or acutely deteriorating asthma.
\*\*Systemic effects\*\*
Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods. These effects are much less likely to occur with inhalation treatment than with oral corticosteroids.
Possible systemic effects include Cushing´s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see section 4.8).
\*Visual disturbance\*
Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.
\*\*Effects on bone density\*\*
Potential effects on bone density should be considered, particularly in patients on high doses for prolonged periods that have co-existing risk factors for osteoporosis.
Long-term studies with inhaled budesonide in adults at daily doses of 800 micrograms (metered dose) have not shown any significant effects on bone mineral density. No information regarding the effect of a budesonide/formoterol fumarate dihydrate fixed-dose combination at higher doses is available.
\*\*Adrenal function\*\*
Treatment with supplementary systematic steroids or inhaled budesonide should not be stopped abruptly.
The prolonged treatment with high doses of inhaled corticosteroids, particularly higher than recommended doses, may also result in clinically significant adrenal suppression. Therefore additional systemic corticosteroid cover should be considered during periods of stress such as severe infections or elective surgery. Rapid reduction in the dose of steroids can induce acute adrenal crisis. Symptoms and signs which might be seen in acute adrenal crisis may be somewhat vague but may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, decreased level of consciousness, seizures, hypotension and hypoglycaemia.
Paradoxical bronchospasm
Paradoxical bronchospasm may occur, with an immediate increase in wheezing and shortness of breath, after dosing. If the patient experiences paradoxical bronchospasm DuoResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy instituted, if necessary. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway (see section 4.8).
\*\*Transfer from oral therapy\*\*
If there is any reason to suppose that adrenal function is impaired from previous systemic steroid therapy, care should be taken when transferring patients to a budesonide/formoterol fumarate fixed-dose combination therapy.
The benefits of inhaled budesonide therapy would normally minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Recovery may take a considerable amount of time after cessation of oral steroid therapy and hence oral steroid-dependent patients transferred to inhaled budesonide may remain at risk from impaired adrenal function for some considerable time. In such circumstances hypothalamic pituitary adrenocortical (HPA) axis function should be monitored regularly.
During transfer from oral therapy to a budesonide/formoterol fumarate fixed-dose combination therapy, a generally lower systemic steroid action will be experienced which may result in the appearance of allergic or arthritic symptoms such as rhinitis, eczema and muscle and joint pain. Specific treatment should be initiated for these conditions. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting should occur. In these cases a temporary increase in the dose of oral glucocorticosteroids is sometimes necessary.
\*\*Oral infections\*\*
To minimise the risk of oropharyngeal candida infection, the patient should be instructed to rinse their mouth out with water after inhaling the dose. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations (see section 4.2).
Paediatric population
It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroids is regularly monitored. If growth is slowed, therapy should be re-evaluated with the aim of reducing the dose of inhaled corticosteroid to the lowest dose at which effective control of asthma is maintained, if possible. The benefits of the corticosteroid therapy and the possible risks of growth suppression must be carefully weighed. In addition, consideration should be given to referring the patient to a paediatric respiratory specialist.
Limited data from long-term studies suggest that most children and adolescents treated with inhaled budesonide will ultimately achieve their adult target height. However, an initial small but transient reduction in growth (approximately 1 cm) has been observed. This generally occurs within the first year of treatment.
\*\*COPD population\*\*
There are no clinical study data on DuoResp Spiromax available in COPD patients with a pre-bronchodilator FEV1 >50% predicted normal and with a post-bronchodilator FEV1 <70% predicted normal (see section 5.1).
\*Pneumonia\*
An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.
There is no conclusive clinical evidence for intra-class differences in the magnitude of the pneumonia risk among inhaled corticosteroid products.
Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of such infections overlap with the symptoms of COPD exacerbations.
Risk factors for pneumonia in patients with COPD include current smoking, older age, low body mass index (BMI) and severe COPD.
\*\*Interaction with other medicinal products\*\*
Concomitant treatment with itraconazole, ritonavir or other potent CYP3A4 inhibitors should be avoided (see section 4.5). If this is not possible the time interval between administrations of the interacting medicinal products should be as long as possible. In patients using potent CYP3A4 inhibitors, a budesonide/formoterol fumarate fixed-dose combination is not recommended.
\*\*Caution with special diseases\*\*
A fixed-dose combination of budesonide and formoterol fumarate dihydrate should be administered with caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurysm or other severe cardiovascular disorders, such as ischaemic heart disease, tachyarrhythmias or severe heart failure.
Caution should be observed when treating patients with prolongation of the QTc-interval. Formoterol itself may induce prolongation of the QTc-interval.
The need for, and dose of inhaled corticosteroids should be re-evaluated in patients with active or quiescent pulmonary tuberculosis, fungal and viral infections in the airways.
Additional blood glucose controls should be considered in diabetic patients.
\*\*β2 adrenoceptor agonists\*\*
Potentially serious hypokalaemia may result from high doses of β2 adrenoceptor agonists. Concomitant treatment of β2 adrenoceptor agonists with medicinal products which can induce hypokalaemia or potentiate a hypokalaemic effect, e.g. xanthine-derivatives, steroids and diuretics, may add to a possible hypokalaemic effect of the β2 adrenoceptor agonist.
Treatment with β2 adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Particular caution is recommended in unstable asthma with variable use of rescue bronchodilators, in acute severe asthma as the associated risk may be augmented by hypoxia and in other conditions when the likelihood for hypokalaemia is increased. It is recommended that serum potassium levels are monitored during these circumstances.
\*\*Excipients\*\*
This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.4.5 Interaction with other medicinal products and other forms of interaction
\*\*Pharmacokinetic interactions\*\*
Potent inhibitors of CYP3A4 (e.g. ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors) are likely to markedly increase plasma levels of budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and budesonide should be as long as possible (see section 4.4). In patients using potent CYP3A4 inhibitors, a fixed-dose combination of budesonide and formoterol fumarate dihydrate maintenance and reliever therapy is not recommended.
The potent CYP3A4 inhibitor ketoconazole, 200 mg once daily, increased plasma levels of concomitantly orally administered budesonide (single dose 3 mg) on average six-fold. When ketoconazole was administered 12 hours after budesonide the concentration was on average increased only three-fold showing that separation of the administration times can reduce the increase in plasma levels. Limited data about this interaction for high-dose inhaled budesonide indicates that marked increases in plasma levels (on average four fold) may occur if itraconazole, 200 mg once daily, is administered concomitantly with inhaled budesonide (single dose of 1000 micrograms).
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side- effects.
\*\*Pharmacodynamic interactions\*\*
β adrenergic blockers can weaken or inhibit the effect of formoterol. A fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate should therefore not be given together with \*\*β\*\* adrenergic blockers (including eye drops) unless there are compelling reasons.
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine) and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.
In addition L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β2 sympathomimetics.
Concomitant treatment with monoamine oxidase inhibitors including medicinal products with similar properties such as furazolidone and procarbazine may precipitate hypertensive reactions.
There is an elevated risk of arrhythmias in patients receiving concomitant anaesthesia with halogenated hydrocarbons.
Concomitant use of other \*\*β\*\* adrenergic medicinal products and anticholinergic medicinal products can have a potentially additive bronchodilating effect.
Hypokalaemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.
Budesonide and formoterol have not been observed to interact with any other medicinal products used in the treatment of asthma.
\*\*Paediatric population\*\*
Interaction studies have only been performed in adults.4.6 Fertility, pregnancy and lactation
\*\*Pregnancy\*\*
For a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate or the concomitant treatment with formoterol and budesonide, no clinical data on exposed pregnancies are available. Data from an embryo-fetal development study in the rat, showed no evidence of any additional effect from the combination.
There are no adequate data from use of formoterol in pregnant women. In animal studies formoterol has caused adverse reactions in reproduction studies at very high systemic exposure levels (see section 5.3).
Data on approximately 2000 exposed pregnancies indicate no increased teratogenic risk associated with the use of inhaled budesonide. In animal studies glucocorticosteroids have been shown to induce malformations (see section 5.3). This is not likely to be relevant for humans given recommended doses.
Animal studies have also identified an involvement of excess prenatal glucocorticoids in increased risks for intrauterine growth retardation, adult cardiovascular disease and permanent changes in glucocorticoid receptor density, neurotransmitter turnover and behaviour at exposures below the teratogenic dose range.
During pregnancy, a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate should only be used when the benefits outweigh the potential risks. The lowest effective dose of budesonide needed to maintain adequate asthma control should be used.
\*\*Breast-feeding\*\*
Budesonide is excreted in breast milk. However, at therapeutic doses no effects on the suckling child are anticipated. It is not known whether formoterol passes into human breast milk. In rats, small amounts of formoterol have been detected in maternal milk. Administration of a fixed-dose combination therapy of budesonide and formoterol fumarate dihydrate to women who are breast-feeding should only be considered if the expected benefit to the mother is greater than any possible risk to the child.
\*\*Fertility\*\*
There is no data available on the potential effect of budesonide on fertility. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure (see section 5.3).4.7 Effects on ability to drive and use machines
DuoResp Spiromax has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*Summary of the safety profile\*\*
Since DuoResp Spiromax contains both budesonide and formoterol, the same pattern of adverse reactions as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common adverse reactions are pharmacologically predictable adverse reactions of β2 adrenoceptor agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment. In a 3-year clinical trial with budesonide in COPD, skin bruises and pneumonia occurred at a frequency of 10% and 6%, respectively, compared with 4% and 3% in the placebo group (p<0.001 and p<0.01, respectively).
\*\*Tabulated list of adverse reactions\*\*
Adverse reactions, which have been associated with budesonide or formoterol, are given below and listed by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, < 1/100), rare (≥1/10,000, < 1/1,000), very rare (<1/10,000) and not known (cannot be estimated from the available data).
\*\*Table 1\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reaction\*\* |
| Infections and infestations | Common | Candida infections in the oropharynx, pneumonia (in COPD patients) |
| Immune system disorders | Rare | Immediate and delayed hypersensitivity reactions, e.g. exanthema, urticaria, pruritus, dermatitis, angioedema and anaphylactic reaction |
| Endocrine disorders | Very rare | Cushing´s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density |
| Metabolism and nutrition disorders | Rare | Hypokalaemia |
| Very rare | Hyperglycaemia |
| Psychiatric disorders | Uncommon | Aggression, psychomotor hyperactivity, anxiety, sleep disorders |
| Very rare | Depression, behavioural changes (predominantly in children) |
| Nervous system disorders | Common | Headache, tremor |
| Uncommon | Dizziness |
| Very rare | Taste disturbances |
| Eye disorders | Very rare | Cataract and glaucoma |
| Uncommon | Vision, blurred (see also section 4.4) |
| Cardiac disorders | Common | Palpitations |
| Uncommon | Tachycardia |
| Rare | Cardiac arrhythmias, e.g. atrial fibrillation, supraventricular tachycardia, extrasystoles |
| Very rare | Angina pectoris. Prolongation of QTc-interval |
| Vascular disorders | Very rare | Variations in blood pressure |
| Respiratory, thoracic and mediastinal disorders | Common | Mild irritation in the throat, coughing, Dysphonia including hoarseness |
| Rare | Bronchospasm |
| Very rare | Paradoxical bronchospasm |
| Gastrointestinal disorders | Uncommon | Nausea |
| Skin and subcutaneous tissue disorders | Uncommon | Bruises |
| Musculoskeletal and connective tissue disorders | Uncommon | Muscle cramps |
\*\*Description of selected adverse reactions\*\*
Candida infection in the oropharynx is due to active substance deposition. Advising the patient to rinse the mouth out with water after each dose will minimise the risk. Oropharyngeal Candida infection usually responds to topical anti-fungal treatment without the need to discontinue the inhaled corticosteroid. If oropharyngeal thrush occurs, patients should also rinse their mouth with water after the as-needed inhalations.
Paradoxical bronchospasm may occur very rarely, affecting less than 1 in 10,000 people, with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting inhaled bronchodilator and should be treated straightaway. DuoResp Spiromax should be discontinued immediately, the patient should be assessed and an alternative therapy is instituted if necessary (see section 4.4).
Systemic effects of inhaled corticosteroids may occur, particularly at high doses prescribed for long periods. These effects are much less likely to occur than with oral corticosteroids. Possible systemic effects include Cushing´s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract and glaucoma. Increased susceptibility to infections and impairment of the ability to adapt to stress may also occur. Effects are probably dependent on dose, exposure time, concomitant and previous steroid exposure and individual sensitivity.
Treatment with β2 adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
\*\*Reporting of suspected adverse reactions\*\*
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
An overdose of formoterol would likely lead to effects that are typical for β2 adrenoceptor agonists: tremor, headache, palpitations. Symptoms reported from isolated cases are tachycardia, hyperglycaemia, hypokalaemia, prolonged QTc-interval, arrhythmia, nausea and vomiting. Supportive and symptomatic treatment may be indicated. A dose of 90 micrograms administered during three hours in patients with acute bronchial obstruction raised no safety concerns.
Acute overdose with budesonide, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses, systemic glucocorticosteroid effects, such as hypercorticism and adrenal suppression, may appear.
If DuoResp Spiromax therapy has to be withdrawn due to overdose of the formoterol component of the medicinal product, provision of appropriate inhaled corticosteroid therapy must be considered.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for obstructive airway diseases, adrenergics and other drugs for obstructive airway diseases.
ATC code: R03AK07
\*\*Mechanism of action and pharmacodynamic effects\*\*
DuoResp Spiromax contains formoterol and budesonide, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations. The specific properties of budesonide and formoterol allow the combination to be used either as maintenance and reliever therapy, or as maintenance treatment of asthma.
\*Budesonide\*
Budesonide is a glucocorticosteroid which when inhaled has a dose-dependent anti-inflammatory action in the airways, resulting in reduced symptoms and fewer asthma exacerbations. Inhaled budesonide has less severe adverse reactions than systemic corticosteroids. The exact mechanism responsible for the anti-inflammatory effect of glucocorticosteroids is unknown.
\*Formoterol\*
Formoterol is a selective β2 adrenoceptor agonist that when inhaled results in rapid and long-acting relaxation of bronchial smooth muscle in patients with reversible airways obstruction. The bronchodilating effect is dose- dependent, with an onset of effect within 1-3 minutes. The duration of effect is at least 12 hours after a single dose.
\*\*Clinical efficacy and safety\*\*
\*\*\*Asthma\*\*\*
\*Budesonide/formoterol maintenance therapy\*
Clinical studies in adults have shown that the addition of formoterol to budesonide improved asthma symptoms and lung function, and reduced exacerbations.
In two 12-week studies the effect on lung function of budesonide/formoterol was equal to that of the free combination of budesonide and formoterol, and exceeded that of budesonide alone. All treatment arms used a short-acting β2 adrenoceptor agonist as needed. There was no sign of attenuation of the anti-asthmatic effect over time.
\*Budesonide/formoterol maintenance and reliever therapy\*
A total of 12076 asthma patients were included in 5 double-blind clinical studies (4447 were randomised to budesonide/formoterol maintenance and reliever therapy) for 6 or 12 months. Patients were required to be symptomatic despite use of inhaled glucocorticosteroids.
Budesonide/formoterol maintenance and reliever therapy provided statistically significant and clinically meaningful reductions in severe exacerbations for all comparisons in all 5 studies. This included a comparison with budesonide/formoterol at a higher maintenance dose with terbutaline as reliever (study 735) and budesonide/formoterol at the same maintenance dose with either formoterol or terbutaline as reliever (study 734) (see table 2). In Study 735, lung function, symptom control, and reliever use were similar in all treatment groups. In Study 734, symptoms and reliever use were reduced and lung function improved, compared with both comparator treatments. In the 5 studies combined, patients receiving budesonide/formoterol maintenance and reliever therapy used, on average, no reliever inhalations on 57% of treatment days. There was no sign of development of tolerance over time.
\*\*Table 2 Overview of severe exacerbations in clinical studies (budesonide / formoterol maintenance and reliever therapy)\*\*
| | | | | |
| --- | --- | --- | --- | --- |
| \*\*Study No. Duration\*\* | \*\*Treatment groups\*\* | \*\*N\*\* | \*\*Severe exacerbations\*\*a | |
| \*\*Events\*\* | \*\*Events/ patient-year\*\* |
| \*\*Study 735\*\* \*\*6 months\*\* | \*\*Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + as needed\*\* | \*\*1103\*\* | \*\*125\*\* | \*\*0.23\*\*b |
| Budesonide/Formoterol Fumarate Dihydrate 320/9 µg bd + terbutaline 0.4 mg as needed | 1099 | 173 | 0.32 |
| Salmeterol/fluticasone 2 x 25/125 µg bd + terbutaline 0.4 mg as needed | 1119 | 208 | 0.38 |
| \*\*Study 734\*\* \*\*12 months\*\* | \*\*Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + as needed\*\* | \*\*1107\*\* | \*\*194\*\* | \*\*0.19\*\*b |
| Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + formoterol 4.5 µg as needed | 1137 | 296 | 0.29 |
| Budesonide/Formoterol Fumarate Dihydrate 160/4.5 µg bd + terbutaline 0.4 mg as needed | 1138 | 377 | 0.37 |
aHospitalisation/emergency room treatment or treatment with oral steroids
bReduction in exacerbation rate is statistically significant (P value <0.01) for both comparisons
Comparable efficacy and safety in adolescents and adults was demonstrated in 6 double-blind studies, comprising the 5 studies mentioned above and an additional study using a higher maintenance dose of 160/4.5 micrograms, two inhalations twice daily. These assessments were based on a total of 14385 asthma patients of whom 1847 were adolescents. The number of adolescent patients taking more than 8 inhalations on at least one day as part of budesonide/formoterol maintenance and reliever therapy was limited and such use was infrequent.
In 2 other studies with patients seeking medical attention due to acute asthma symptoms, budesonide/formoterol provided rapid and effective relief of bronchoconstriction similar to salbutamol and formoterol.
\*\*\*Budesonide/formoterol reliever therapy (Therapy C in Section 4.2)\*\*\*
A total of 8064 adult and adolescent asthma patients with mild asthma were included in 2 randomised, double-blind, double-dummy, placebo-controlled, 52-week efficacy and safety studies (SYGMA 1 and SYGMA 2). Across both studies, 889 patients were adolescents. At study entry, patients were required to be uncontrolled on only short-acting inhaled bronchodilator as needed or controlled on a low dose of inhaled corticosteroids or a leukotriene receptor agonist plus a short- acting inhaled bronchodilator as needed.
A further 1565 adult asthma patients were included in 2 randomised, open-label, 52-week investigator-sponsored efficacy and safety studies (Novel START and PRACTICAL). In Novel START, patients had used as-needed short-acting inhaled bronchodilator (without any other asthma medication) in the 3 months before study entry, while in PRACTICAL, patients had used as-needed short-acting inhaled bronchodilator alone or a low to medium dose of inhaled corticosteroids plus short- acting inhaled bronchodilator as needed at study entry.
\*Exacerbation rate\*
The primary endpoint in SYGMA 2 and PRACTICAL was the annual severe exacerbation rate, while the rate of all exacerbations was the primary endpoint in Novel START. The primary endpoint in SYGMA 1 was 'well-controlled asthma weeks' (WCAW), a composite measure of asthma control.
Table 3 summarises the rate of exacerbations by treatment group in the 4 studies. SYGMA 2 showed that the severe exacerbation rate with budesonide/formoterol reliever therapy was comparable to budesonide maintenance treatment plus a short- acting β2 agonist (SABA) reliever and that this protection against severe exacerbations was achieved with a 75% reduction in median inhaled steroid load. In PRACTICAL, a statistically significant reduction in the severe exacerbation rate was observed with budesonide/formoterol reliever therapy compared with budesonide maintenance treatment plus a SABA reliever. In Novel START, budesonide/formoterol reliever therapy provided a statistically significant reduction in the exacerbation rate compared with a SABA reliever.
\*\*Table 3 Overview of asthma exacerbations in clinical studies (budesonide/formoterol reliever therapy)\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Study No. Duration Blinding\*\* | \*\*Treatment groupsa\*\* | \*\*n\*\* | \*\*Exacerbations\*\*b | | \*\*Rate ratio\*\* \*\*(2-sided 95% CI) versus budesonide/ formoterol\*\* |
| \*\*Events\*\* | \*\*Events/ patient-year\*\* |
| \*\*Severe exacerbations (primary endpoint in SYGMA 2 and PRACTICAL, secondary endpoint in SYGMA 1)\*\* | | | | | |
| \*\*SYGMA 2\*\* \*\*12 months\*\* \*\*Double blind\*\* | \*\*Placebo bd + budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*2084\*\* | \*\*217\*\* | \*\*0.11\*\* | \*\*NA\*\* |
| Budesonide/formoterol 160 µg bd + terbutaline 0.4 mg as needed | 2083 | 221 | 0.12 | 0.97 (0.78, 1.20) p = 0.754c |
| \*\*PRACTICAL\*\* \*\*12 months\*\* \*\*Open label\*\* | \*\*Budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*437\*\* | \*\*48\*\* | \*\*0.119\*\* | NA |
| Budesonide/formoterol 160/4.5 µg bd + terbutaline 0.4 mg as needed | 448 | 68 | 0.172 | 0.69 (0.48, 1.00) p = 0.049 |
| \*\*SYGMA 1\*\* \*\*12 months\*\* \*\*Double blind\*\* | \*\*Placebo bd + budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*1277\*\* | \*\*77\*\* | \*\*0.07\*\* | NA |
| Placebo bd + terbutaline 0.4 mg as needed | 1277 | 188 | 0.20 | 0.36 (0.27, 0.49) p <0.001 |
| Budesonide 160 µg bd + terbutaline 0.4 mg as needed | 1282 | 89 | 0.09 | 0.83 (0.59, 1.16) p = 0.279 |
| \*\*All exacerbations (primary endpoint in Novel START)\*\* | | | | | |
| \*\*Novel START\*\* \*\*12 months\*\* \*\*Open label\*\* | \*\*Budesonide/formoterol 160/4.5 µg as needed\*\* | \*\*220\*\* | \*\*37\*\* | \*\*0.195\*\* | NA |
| Budesonide 160 µg bd + salbutamol 200 µg as needed | 225 | 32 | 0.175 | 1.12 (0.70, 1.79) p = 0.65 |
| Salbutamol 200 µg as needed | 223 | 74 | 0.400 | 0.49 (0.33, 0.72) p < 0.001 |
a Budesonide 160 µg (delivered dose) corresponds to budesonide 200 µg (metered dose).
b Severe exacerbations were defined as deteriorating asthma requiring treatment with systemic steroids for at least 3 days, or hospital admission or emergency room visit due to asthma requiring systemic steroids. All exacerbations in Novel START were defined as worsening of asthma resulting in an urgent medical review or a prescription of systemic steroids for any duration or high β2 agonist use.
c The upper limit (1.16) of the 1-sided 95% CI for the rate ratio was below the pre- specified non-inferiority limit (1.20).
\*Asthma control\*
In SYGMA 1, in terms of the WCAW, budesonide/formoterol reliever therapy was superior to a SABA reliever (mean percentage well controlled asthma weeks: 34.4% versus 31.1%, respectively; odds ratio 1.14 [95% CI 1.00 to 1.30], p-value = 0.046) and was inferior to budesonide maintenance treatment plus a SABA reliever (34.4% versus 44.4% weeks, respectively; odds ratio 0.64 [95% CI 0.57 to 0.73], lower limit of the CI ≥ 0.8 for non-inferiority).
Improvements in asthma control (as defined by ACQ5) in patients using budesonide/formoterol reliever therapy were superior to improvements in patients using a SABA as needed (SYGMA 1: mean difference −0.15, 95% CI −0.20 to −0.11, p-value < 0.001; Novel START: −0.15; 95% CI, −0.24 to −0.06). In the SYGMA studies and Novel START, improvements in asthma control were lower for budesonide/formoterol reliever therapy compared to budesonide maintenance treatment plus a SABA reliever (SYGMA 1: 0.15, 95% CI 0.10 to 0.20; SYGMA 2: 0.11, 95% CI 0.07 to 0.15, both p-values < 0.001; Novel START: 0.14; 95% CI, 0.05 to 0.23) but there was no difference between the groups in PRACTICAL (0.06, 95% CI, −0.005 to 0.12, p =0.07). For all comparisons, the mean difference in treatment effect upon ACQ5 were not clinically meaningful (as assessed by a difference of greater than or equal to 0.5). These results were observed in a clinical study setting with considerably higher adherence to budesonide maintenance dosing than expected in real life.
\*Lung function\*
In SYGMA 1, improvements in mean pre-bronchodilator FEV1 compared to baseline were statistically significantly larger for patients on budesonide/formoterol reliever therapy compared to patients using a SABA reliever (53.8 mL; 95% CI 29.1 to 78.5; p <0.001).
In both SYGMA studies, statistically significantly smaller improvements in FEV1 were observed for budesonide/formoterol reliever therapy compared to budesonide maintenance treatment plus a SABA reliever (SYGMA 1: −54.3 mL; 95% CI −78.8 to −29.8; p <0.001; SYGMA 2: −32.6 mL; 95% CI −53.7 to −11.4; p = 0.003); For both comparisons, the mean differences in treatment effect were small (approximately 30 to 55 mL, equating to approximately 2% of the baseline mean). In Novel START and PRACTICAL, there were no significant differences in FEV1 versus SABA (Novel START: 0.03 L; 95% CI, −0.006 to 0.07) or versus budesonide maintenance treatment plus a SABA reliever (Novel START: 0.004 L; 95% CI, −0.03 to 0.04; PRACTICAL: 0.006 L; 95% CI −0.026 to 0.04; p = 0·69).
\*COPD\*
In two 12-month studies, the effect on lung function and the rate of exacerbation (defined as courses of oral steroids and/or course of antibiotics and/or hospitalisations) in patients with moderate to severe COPD was evaluated. The inclusion criteria for both studies was pre-bronchodilator FEV1 <50% predicted normal. Median post-bronchodilator FEV1 at inclusion in the trials was 42% predicted normal.. The mean number of exacerbations per year (as defined above) was significantly reduced with budesonide/formoterol as compared with treatment with formoterol alone or placebo (mean rate 1.4 compared with 1.8-1.9 in the placebo/formoterol group). The mean number of days on oral corticosteroids/patient during the 12 months was slightly reduced in the budesonide/formoterol group (7-8 days/patient/year compared with 11-12 and 9-12 days in the placebo and formoterol groups, respectively). For changes in lung-function parameters, such as FEV1, budesonide/formoterol was not superior to treatment with formoterol alone.
\*\*Peak Inspiratory Flow Rate through the Spiromax Device\*\*
A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD – aged >50 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device(containing placebo). The impact of enhanced training in dry powder inhaler inhalation technique on inhalation speed and volume was also assessed in these subject groups. The data from the study indicated that regardless of age and underlying disease severity, children, adolescents and adults with asthma as well as patients with COPD were able to able to achieve inspiratory flow rates through the Spiromax device that were similar to those generated through the marketed multi-dose dry powder inhaler device. The mean PIFR achieved by patients with asthma or COPD was over 60L/min, a flow rate at which both devices studied are known to deliver comparable amounts of drug to the lungs. Very few patients had PIFRs below 40L/min; when PIFRs were less than 40L/min there appeared to be no clustering by age or disease severity.5.2 Pharmacokinetic properties
\*\*Absorption\*\*
The fixed-dose combination of budesonide and formoterol, and the corresponding monoproducts have been shown to be bioequivalent with regard to systemic exposure of budesonide and formoterol, respectively. In spite of this, a small increase in cortisol suppression was seen after administration of fixed-dose combination compared to the monoproducts. The difference is considered not to have an impact on clinical safety.
There was no evidence of pharmacokinetic interactions between budesonide and formoterol.
Pharmacokinetic parameters for the respective substances were comparable after the administration of budesonide and formoterol as monoproducts or as the fixed-dose combination. For budesonide, AUC was slightly higher, rate of absorption more rapid and maximal plasma concentration higher after administration of the fixed combination. For formoterol, maximal plasma concentration was similar after administration of the fixed combination. Inhaled budesonide is rapidly absorbed and the maximum plasma concentration is reached within 30 minutes after inhalation. In studies, mean lung deposition of budesonide after inhalation via the powder inhaler ranged from 32% to 44% of the delivered dose. The systemic bioavailability is approximately 49% of the delivered dose. In children 6-16 years of age the lung deposition falls in the same range as in adults for the same given dose. The resulting plasma concentrations were not determined.
Inhaled formoterol is rapidly absorbed and the maximum plasma concentration is reached within 10 minutes after inhalation. In studies the mean lung deposition of formoterol after inhalation via the powder inhaler ranged from 28% to 49% of the delivered dose. The systemic bioavailability is about 61% of the delivered dose.
\*\*Distribution\*\*
Plasma protein binding is approximately 50% for formoterol and 90% for budesonide. Volume of distribution is about 4 L/kg for formoterol and 3 L/kg for budesonide. Formoterol is inactivated via conjugation reactions (active O-demethylated and deformylated metabolites are formed, but they are seen mainly as inactivated conjugates). Budesonide undergoes an extensive degree (approximately 90%) of biotransformation on first passage through the liver to metabolites of low glucocorticosteroid activity. The glucocorticosteroid activity of the major metabolites, 6-beta-hydroxy-budesonide and 16-alfa-hydroxy-prednisolone, is less than 1% of that of budesonide. There are no indications of any metabolic interactions or any displacement reactions between formoterol and budesonide.
\*\*Elimination\*\*
The major part of a dose of formoterol is transformed by liver metabolism followed by renal elimination. After inhalation, 8% to 13% of the delivered dose of formoterol is excreted unmetabolised in the urine. Formoterol has a high systemic clearance (approximately 1.4 L/min) and the terminal elimination half-life averages 17 hours.
Budesonide is eliminated via metabolism mainly catalysed by the enzyme CYP3A4. The metabolites of budesonide are eliminated in urine as such or in conjugated form. Only negligible amounts of unchanged budesonide have been detected in the urine. Budesonide has a high systemic clearance (approximately 1.2 L/min) and the plasma elimination half-life after i.v. dosing averages 4 hours.
\*\*Pharmacokinetic/pharmacodynamic relationship(s)\*\*
The pharmacokinetics of budesonide or formoterol in children and patients with renal failure are unknown. The exposure of budesonide and formoterol may be increased in patients with liver disease.
\*\*DuoResp Spiromax pharmacokinetic profile\*\*
In pharmacokinetic studies with and without a charcoal blockage, DuoResp Spiromax was evaluated by comparing it with an alternative authorised fixed-dose combination inhaled product containing the same active substances, budesonide and formoterol and has been shown to be equivalent in both systemic exposure (safety) and pulmonary deposition (efficacy).
\*\*Linearity/non-linearity\*\*
Systemic exposure for both budesonide and formoterol correlates in a linear fashion to administered dose.5.3 Preclinical safety data
The toxicity observed in animal studies with budesonide and formoterol, given in combination or separately, were effects associated with exaggerated pharmacological activity.
In animal reproduction studies, corticosteroids such as budesonide have been shown to induce malformations (cleft palate, skeletal malformations). However, these animal experimental results do not seem to be relevant in humans at the recommended doses. Animal reproduction studies with formoterol have shown a somewhat reduced fertility in male rats at high systemic exposure and implantation losses as well as decreased early postnatal survival and birth weight at considerably higher systemic exposures than those reached during clinical use. However, these animal experimental results do not seem to be relevant in humans.
## Pharmaceutical Particulars
6.1 List of excipients
Lactose monohydrate (which contains milk proteins).6.2 Incompatibilities
Not applicable.6.3 Shelf life
3 years.
After opening the foil wrap: 12 months.6.4 Special precautions for storage
Do not store above 25°C.
Keep the mouthpiece cover closed after removal of the foil wrap.6.5 Nature and contents of container
The inhaler is white with a semi-transparent wine red mouthpiece cover. The drug/mucosal contact parts of the inhaler are made of acrylonitrile butadiene styrene (ABS), polyethylene (PE), and polypropylene (PP). Each inhaler contains 120 doses and is foil-wrapped.
Pack sizes of 1, 2 or 3 inhalers.
Not all pack-sizes may be marketed.6.6 Special precautions for disposal and other handling
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Company Detail Path
- /organization/teva-pharma-b-v
